Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas

International Journal of Cancer

Volumn 85, Issue 1, 2000, Pages 104-112

  Johnson, Timothy A ^a,b   Press, Oliver W ^a,b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; CISPLATIN; CYTARABINE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; FLUDARABINE PHOSPHATE; MONOCLONAL ANTIBODY I 131; NUCLEOSIDE ANALOG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; BURKITT LYMPHOMA; CELL SURVIVAL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; IODINE RADIOISOTOPES; LYMPHOMA, LARGE-CELL, DIFFUSE; RADIOIMMUNOTHERAPY; TETRAZOLIUM SALTS; THIAZOLES; TRYPAN BLUE; TUMOR CELLS, CULTURED;

EID: 0033991523     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(20000101)85:1<104::AID-IJC19>3.0.CO;2-G     Document Type: Article

References (20)

1. BUCHSBAUM, D.J., KHAZAELI, M.B., DAVIS, M.A. and LAWRENCE, T.S., Sensitization of radiolabeled monoclonal antibody therapy using bromodeoxyuridine. Cancer, 73, S999-S1005 (1994).
2. DEMIDEN, A., LAM, T., ALAS, S., HARIHARAN, K., HANNA, N. and BONAVIDA, B., Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B-cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother. Radiopharm., 12, 177-186 (1997).
3. DOUPLE, E.B., Interactions between platinum coordination complexes and radiation. In: B.T. HILL and A.S. BELLAMY (eds.), Antitumor drug-radiation interactions, pp. 171-184, CRC Press, Boca Raton, FL (1990).
4. GIOCANTI, N., HENNEQUIN, C., BALOSSO, J., MAHLER, M. and FAVAUDON, V., DNA repair and cell cycle interactions in radiation sensitization by the topoisomerase II poison etoposide. Cancer Res., 53, 2105-2110 (1993).
5. HADDOCK, M.G., AMES, M.M. and BONNER, J.A., Assessing the interaction of irradiation with etoposide or idarubicin. Mayo Clin. Proc., 70, 1053-1060 (1995).
6. HENNEQUIN, C., GIOCANTI, N., BALOSSO, J. and FAVAUDON, V., Interaction of ionizing radiation with the topoisomerase poison camptothecin in growing V-79 and HeLa cells. Cancer Res., 54, 1720-1728 (1994).
7. HILL, B.T. and BELLAMY, A.S., An overview of experimental investigations of interactions between certain antitumor drugs and X-irradiation in vitro. Adv. Radiat. Biol., 11, 211-267 (1984).
8. HUBERT, J.J., Bioassay, pp. 71-74, Kendall/Hunt, Dubuque, IA (1980).
9. KAMINSKI, M.S., ZASADNY, K.R., FRANCIS, I.R., FENNER, M.C., ROSS, C.W., MILIK, A.W., ESTES, J., TUCK, M., REGAN, D., FISHER, S., GLENN, S.D. and WAHL, R.L., Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J. clin. Oncol., 14, 1974-1991 (1996).
10. KANO, Y., SUZUKI, K., AKUTSU, M., SUDA, K., INOUE, Y., YOSHIDA, M., SAKAMOTO, S. and MIURA, Y., Effects of CPT-11 in combination with other anti-cancer agents in culture. Int. J. Cancer, 50, 604-610 (1992).
11. MCGINN, C.J., SHEWACH, D.S. and LAWRENCE, T.S., Radiosensitizing nucleotides. J. nat. Cancer Inst., 88, 1193-1203 (1996).
12. MCLAUGHLIN, P. and 15 OTHERS, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. clin. Oncol., 16, 2825-2833 (1998).
13. PRESS, O.W. and 12 OTHERS, Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med., 329, 1219-1224 (1993).
14. PRESS, O.W., EARY, J.F., APPELBAUM, F.R., MARTIN, P.J., NELP, W.B., GLENN, S., FISHER, D.R., PORTER, B., MATTHEWS, D.C., GOOLEY, T. and BERNSTEIN, I.D., A phase II trial of 1-131-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphomas. Lancet, 346, 336-340 (1995).
15. PRESS, O.W., FARR, A.G., BORROZ, K.I., ANDERSON, S.K. and MARTIN, P.J., Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res., 49, 4906-4912 (1989).
16. RAAPHORST, G.P., WANG, G., STEWART, D. and NG, C.E., Concomitant low dose-rate irradiation and cisplatin treatment in ovarian carcinoma cell lines sensitive and resistant to cisplatin treatment. Int. J. Radiat. Biol., 69, 623-631 (1996).
17. ROFFLER, S.R., CHAN, J. and YEH, M.Y., Potentiation of radioimmunotherapy by inhibition of topoisomerase I. Cancer Res., 54, 1276-1285 (1994).
18. SHAN, D., LEDBETTER, J.A. and PRESS, O.W., Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood, 91, 1644-1652 (1998).
19. STEEL, G.G. and PECKHAM, M.J., Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int. J. Radiat. Oncol. Biol. Phys., 5, 85-91 (1979).
20. SZUMIEL, I., BURACZEWSKA, I., GRADZKA, I. and GASINSKA, A., Effects of topoisomerase I-targeted drugs on radiation response of LS178Y sublines differentially radiation and drug sensitive. Int. J. Radiat. Biol., 67, 441-448 (1995).